Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1No longer available 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Glioblastoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × gallium maltolate × Clear all
NCT06404034 2026-03-04

Expanded Access to Gallium Maltolate (GaM)

Imaging Biometrics, LLC

No longer available
CNS

Glioblastoma

NCT00050687 2011-01-28

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Titan Pharmaceuticals

Phase 1/2 Terminated
GenitourinaryLymphoidPlasma cell

Urinary Bladder Neoplasms, Lymphoma, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡